Duncan S. Stearns

Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma

Daniel M. Feinberg, Vinayak Uppin, Saada K. Eid, Claire E. Fritz et autres

BACKGROUND: CAR-T therapy has revolutionized treatments for many hematologic malignancies, but it has shown far less efficacy against solid tumors. One reason for this lower efficacy in solid tumors is increased antigen heterogeneity. This study utilizes a ligand-based CAR-T approach, which allows …

us (code pays fourni par la source)

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study

Tanja Andrea Gruber, Sima C. Jeha, Rebecca J. Deyell, Victor Anthony Lewis et autres

Background Acute lymphoblastic leukaemia in infants remains a therapeutic challenge. In preclinical studies we previously identified bortezomib and vorinostat as active agents against KMT2A rearranged ( KMT2A r) leukaemia. The aim of this study was to determine the tolerability of incorporating bortezomib …

us, ca (code pays fourni par la source)

Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

Amar J. Gajjar, Anita Mahajan, Tejus Bale, Daniel C. Bowers et autres

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that …

us, in (code pays fourni par la source)

NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY

Robert A. Avery, Zhifan Jiang, Abhijeet Parida, Robert Listernick et autres

Abstract BACKGROUND NF1-OPGs are amorphous tumors involving either single or multiple locations (optic nerve, chiasm, tract) along the anterior visual pathway (AVP). In this prospective study, we investigated how volumetric MRI measures of the AVP as well as other clinical variables are …

us, au, ca (code pays fourni par la source)

NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY

Michael J. Fisher, Peter M K de Blank, Robert Listernick, Grant Liu et autres

Abstract BACKGROUND Treatment and clinical management decisions for children with NF1-OPGs remain challenging as most existing data are retrospective and have not included standardized visual outcomes. In this study, we prospectively enrolled newly diagnosed NF1-OPGs and performed standardized neuro-oncology and ophthalmology assessments …

us, au, ca (code pays fourni par la source)

Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study

Ayse B. Ercan, Melyssa D. Aronson, Nicholas R. Fernandez, Yuan Chang et autres

ca, om, us, pk, es, iq, be, au, il, lb, it, gb, sk, cz, ph, no, se, pt, jo, ir, ch, sa, in, tr, br (code pays fourni par la source)

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Tanja Andrea Gruber, Minxuan Huang, Sima Jeha, Rebecca J. Deyell et autres

Infants with KMT2A rearranged (KMT2Ar) acute lymphoblastic leukemia (ALL) have a poor prognosis with an event-free-survival (EFS) of 33.6-36.9% on recent Children's Oncology Group and Interfant trials. In preclinical studies, we identified bortezomib and vorinostat as novel active agents in primary KMT2Ar …

us, ca (code pays fourni par la source)

Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program

Zachary T. Rivers, Karyn Ronski, Duncan S. Stearns, Stephanie A. Toll et autres

The Research to Accelerate Cures and Equity (RACE) for Children Act mandates that newly developed targeted oncology drugs be tested in children when molecular targets are relevant to pediatric cancers. In its first year, the RACE for Children Act was effective in …

us (code pays fourni par la source)

Supplementary Figure Legends 1-6, Table Legends 1-4 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Limei Zhou, Daniel J. Picard, Young‐Shin Ra, Meihua Li et autres

Supplementary Figure Legends 1-6, Table Legends 1-4 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Supplementary Table 3 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Limei Zhou, Daniel J. Picard, Young‐Shin Ra, Meihua Li et autres

Supplementary Table 3 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Supplementary Table 1 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Limei Zhou, Daniel J. Picard, Young‐Shin Ra, Meihua Li et autres

Supplementary Table 1 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Supplementary Table 2 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma

Limei Zhou, Daniel J. Picard, Young‐Shin Ra, Meihua Li et autres

Supplementary Table 2 from Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma